Revvity (NYSE:RVTY) Sets New 1-Year High - Here's What Happened

Key Points

• Revvity shares reached a new 52-week high of $168.66, up 2.8% from the prior close, giving the company a market capitalization of approximately $18.57 billion.
• The company exceeded quarterly expectations, reporting adjusted EPS of $1.41 versus the $1.21 consensus and revenue of $729.69 million, though revenue declined 1.3% year over year.
• Analyst sentiment remains cautious: five analysts rate Revvity a Buy and 13 recommend Hold, producing a consensus Hold rating and an average price target of $124.43, well below the recent share price.

Revvity Inc. (NYSE:RVTY - Get Free Report)'s share price reached a new 52-week high on Wednesday. The company traded as high as $168.66 and last traded at $168.11, with a volume of 417,463 shares traded. The stock had previously closed at $161.86.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Royal Bank Of Canada assumed coverage on Revvity in a research note on Tuesday, September 1st. They issued a "sector perform" rating and a $135.00 price target for the company. Evercore restated an "outperform" rating on shares of Revvity in a research note on Wednesday, August 5th. Zacks Research upgraded shares of Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Barclays upped their price objective on shares of Revvity from $115.00 to $160.00 and gave the company an "equal weight" rating in a report on Wednesday, October 7th. Finally, TD Cowen lifted their target price on shares of Revvity from $130.00 to $175.00 and gave the stock a "buy" rating in a research note on Tuesday, October 13th. Five investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $124.43.

Revvity Stock Up 2.8%

The business's 50-day simple moving average is $141.93 and its two-hundred day simple moving average is $111.26. The firm has a market cap of $18.57 billion, a price-to-earnings ratio of 79.27 and a beta of 1.06.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analysts' expectations of $702.96 million. Revvity's revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.18 EPS. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts expect that Revvity Inc. will post 5.36 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity's dividend payout ratio (DPR) is 13.33%.

Insider Activity

In related news, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the completion of the transaction, the insider owned 14,781 shares of the company's stock, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tajinder Vohra sold 7,330 shares of the company's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider owned 6,635 shares in the company, valued at $934,738.80. This trade represents a 52.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 9,045 shares of company stock worth $1,281,439. 0.85% of the stock is owned by insiders.

Hedge Funds Weigh In On Revvity

Several institutional investors have recently modified their holdings of the business. Jupiter Topco LLC acquired a new stake in Revvity during the second quarter worth approximately $961,017,000. BlackRock Inc. acquired a new position in shares of Revvity in the 2nd quarter valued at $852,070,000. Wellington Management Group LLP grew its position in shares of Revvity by 10,653.8% in the 2nd quarter. Wellington Management Group LLP now owns 865,575 shares of the company's stock valued at $96,304,000 after buying an additional 857,526 shares during the last quarter. Primecap Management Co. CA purchased a new position in shares of Revvity in the 2nd quarter valued at $94,921,000. Finally, Bank of America Corp DE purchased a new position in shares of Revvity in the 2nd quarter valued at $87,116,000. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Company Profile

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.